Cell reports. Medicine · 2022
Ad26.COV2.S breakthrough infections induce high titers of neutralizing antibodies against Omicron and other SARS-CoV-2 variants of concern.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kitchin Dale, Richardson Simone I, van der Mescht Mieke A, Motlou Thopisang, Mzindle Nonkululeko, Moyo-Gwete Thandeka, Makhado Zanele, Ayres Frances, Manamela Nelia P, Spencer Holly, Lambson Bronwen, Oosthuysen Brent, Kaldine Haajira, du Pisanie Marizane, Mennen Mathilda, Skelem Sango, Williams Noleen, Ntusi Ntobeko A B, Burgers Wendy A, Gray Glenda G, Bekker Linda-Gail, Boswell Michael T, Rossouw Theresa M, Ueckermann Veronica, Moore Penny L
Аннотация
The Janssen (Johnson & Johnson) Ad26.COV2.S non-replicating viral vector vaccine has been widely deployed for COVID-19 vaccination programs in resource-limited settings. Here we confirm that neutralizing and binding antibody responses to Ad26.COV2.S vaccination are stable for 6 months post-vaccination, when tested against multiple SARS-CoV-2 variants. Secondly, using longitudinal samples from individuals who experienced clinically mild breakthrough infections 4 to 5 months after vaccination, we show dramatically boosted binding antibodies, Fc effector function, and neutralization. These high titer responses are of similar magnitude to humoral immune responses measured in convalescent donors who had been hospitalized with severe illness, and are cross-reactive against diverse SARS-CoV-2 variants, including the neutralization-resistant Omicron (B.1.1.529) variant that currently dominates global infections, as well as SARS-CoV-1. These data have implications for population immunity in areas where the Ad26.COV2.S vaccine has been widely deployed, but where ongoing infections continue to occur at high levels.